| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Neoplasms | 11 | 2023 | 1318 | 1.510 |
Why?
|
| Adenocarcinoma | 8 | 2020 | 1026 | 1.470 |
Why?
|
| Neoadjuvant Therapy | 6 | 2019 | 341 | 1.450 |
Why?
|
| Carcinoma, Hepatocellular | 10 | 2023 | 934 | 1.410 |
Why?
|
| Lymphatic Metastasis | 5 | 2019 | 418 | 1.200 |
Why?
|
| Peripheral Nervous System Diseases | 3 | 2021 | 122 | 0.970 |
Why?
|
| Stomach Neoplasms | 3 | 2021 | 548 | 0.930 |
Why?
|
| Lymph Nodes | 5 | 2019 | 379 | 0.850 |
Why?
|
| Health Services for Transgender Persons | 1 | 2021 | 1 | 0.750 |
Why?
|
| Sex Reassignment Procedures | 1 | 2021 | 15 | 0.750 |
Why?
|
| Gender Identity | 1 | 2021 | 65 | 0.720 |
Why?
|
| Veterans | 7 | 2024 | 1748 | 0.700 |
Why?
|
| Patient Transfer | 1 | 2021 | 105 | 0.700 |
Why?
|
| Cancer Survivors | 2 | 2021 | 211 | 0.700 |
Why?
|
| Natural Language Processing | 2 | 2024 | 63 | 0.690 |
Why?
|
| Transgender Persons | 1 | 2021 | 62 | 0.680 |
Why?
|
| Chemotherapy, Adjuvant | 8 | 2019 | 363 | 0.660 |
Why?
|
| Fatigue | 1 | 2021 | 190 | 0.660 |
Why?
|
| Physician-Patient Relations | 2 | 2021 | 430 | 0.630 |
Why?
|
| Exercise Therapy | 1 | 2021 | 155 | 0.630 |
Why?
|
| Patient-Centered Care | 1 | 2021 | 221 | 0.620 |
Why?
|
| Gastrectomy | 2 | 2021 | 93 | 0.620 |
Why?
|
| Neoplasm Staging | 8 | 2020 | 1275 | 0.580 |
Why?
|
| Antineoplastic Agents | 4 | 2021 | 1691 | 0.560 |
Why?
|
| Attitude of Health Personnel | 2 | 2021 | 677 | 0.560 |
Why?
|
| Rectal Neoplasms | 1 | 2018 | 78 | 0.530 |
Why?
|
| Information Storage and Retrieval | 1 | 2016 | 58 | 0.490 |
Why?
|
| Wearable Electronic Devices | 3 | 2024 | 103 | 0.490 |
Why?
|
| International Classification of Diseases | 1 | 2016 | 90 | 0.480 |
Why?
|
| Aged | 26 | 2024 | 19896 | 0.440 |
Why?
|
| Electronic Health Records | 3 | 2024 | 722 | 0.430 |
Why?
|
| Databases, Factual | 3 | 2018 | 1186 | 0.410 |
Why?
|
| Prostatic Neoplasms | 1 | 2021 | 1549 | 0.390 |
Why?
|
| Hospitals | 3 | 2020 | 398 | 0.380 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2018 | 1251 | 0.370 |
Why?
|
| HIV Infections | 1 | 2023 | 1899 | 0.360 |
Why?
|
| Middle Aged | 21 | 2024 | 26990 | 0.350 |
Why?
|
| Aged, 80 and over | 10 | 2021 | 6607 | 0.350 |
Why?
|
| Retrospective Studies | 16 | 2023 | 16389 | 0.340 |
Why?
|
| Interprofessional Relations | 1 | 2011 | 145 | 0.330 |
Why?
|
| Proportional Hazards Models | 5 | 2020 | 1361 | 0.320 |
Why?
|
| Physician's Role | 1 | 2011 | 168 | 0.320 |
Why?
|
| Gastrointestinal Neoplasms | 2 | 2020 | 81 | 0.310 |
Why?
|
| Algorithms | 1 | 2016 | 1630 | 0.310 |
Why?
|
| Communication | 2 | 2022 | 517 | 0.300 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2019 | 1058 | 0.290 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2019 | 144 | 0.290 |
Why?
|
| Combined Modality Therapy | 3 | 2021 | 1244 | 0.280 |
Why?
|
| Male | 26 | 2024 | 61663 | 0.280 |
Why?
|
| Humans | 36 | 2024 | 125392 | 0.280 |
Why?
|
| Esophagectomy | 2 | 2018 | 64 | 0.280 |
Why?
|
| Chemoradiotherapy | 2 | 2018 | 103 | 0.270 |
Why?
|
| Female | 24 | 2024 | 66885 | 0.250 |
Why?
|
| Colorectal Neoplasms | 1 | 2011 | 576 | 0.240 |
Why?
|
| United States | 12 | 2021 | 10936 | 0.230 |
Why?
|
| Primary Health Care | 1 | 2011 | 777 | 0.230 |
Why?
|
| Neoplasms | 4 | 2024 | 2792 | 0.220 |
Why?
|
| Esophageal Neoplasms | 2 | 2018 | 376 | 0.210 |
Why?
|
| Liver Cirrhosis | 3 | 2020 | 842 | 0.200 |
Why?
|
| Resilience, Psychological | 1 | 2024 | 69 | 0.200 |
Why?
|
| Colonic Neoplasms | 2 | 2017 | 248 | 0.200 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2017 | 668 | 0.190 |
Why?
|
| Adult | 11 | 2021 | 29692 | 0.190 |
Why?
|
| Frailty | 1 | 2024 | 104 | 0.190 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 3 | 2016 | 398 | 0.180 |
Why?
|
| Treatment Outcome | 9 | 2019 | 12412 | 0.180 |
Why?
|
| Chemoradiotherapy, Adjuvant | 2 | 2018 | 29 | 0.180 |
Why?
|
| Disease-Free Survival | 3 | 2018 | 897 | 0.170 |
Why?
|
| Emotions | 2 | 2021 | 357 | 0.170 |
Why?
|
| Palliative Care | 2 | 2018 | 434 | 0.160 |
Why?
|
| Young Adult | 5 | 2021 | 9069 | 0.160 |
Why?
|
| False Negative Reactions | 1 | 2019 | 89 | 0.160 |
Why?
|
| Comorbidity | 3 | 2019 | 1537 | 0.150 |
Why?
|
| Clinical Trials as Topic | 2 | 2021 | 1104 | 0.150 |
Why?
|
| Neoplasm Grading | 1 | 2019 | 272 | 0.150 |
Why?
|
| Hospice Care | 1 | 2018 | 31 | 0.140 |
Why?
|
| Biliary Tract Surgical Procedures | 1 | 2017 | 23 | 0.140 |
Why?
|
| Gallbladder Neoplasms | 1 | 2017 | 15 | 0.140 |
Why?
|
| Rectum | 1 | 2018 | 99 | 0.140 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2017 | 97 | 0.130 |
Why?
|
| Stomach | 1 | 2019 | 270 | 0.130 |
Why?
|
| Preoperative Care | 1 | 2019 | 355 | 0.130 |
Why?
|
| Myasthenia Gravis | 1 | 2017 | 73 | 0.130 |
Why?
|
| Pancreatectomy | 1 | 2017 | 138 | 0.130 |
Why?
|
| Veterans Health | 1 | 2018 | 176 | 0.130 |
Why?
|
| Telemedicine | 1 | 2022 | 439 | 0.130 |
Why?
|
| Cholangiocarcinoma | 1 | 2017 | 107 | 0.130 |
Why?
|
| Bile Duct Neoplasms | 1 | 2017 | 109 | 0.130 |
Why?
|
| Cohort Studies | 7 | 2021 | 4824 | 0.130 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2017 | 128 | 0.130 |
Why?
|
| Socioeconomic Factors | 2 | 2016 | 872 | 0.120 |
Why?
|
| Cognitive Dysfunction | 1 | 2019 | 236 | 0.120 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2017 | 115 | 0.120 |
Why?
|
| Motor Activity | 1 | 2019 | 520 | 0.120 |
Why?
|
| Odds Ratio | 1 | 2019 | 1260 | 0.120 |
Why?
|
| Quality Indicators, Health Care | 1 | 2017 | 219 | 0.120 |
Why?
|
| Adolescent | 5 | 2021 | 19373 | 0.120 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2021 | 735 | 0.120 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2024 | 348 | 0.120 |
Why?
|
| United States Department of Veterans Affairs | 2 | 2016 | 670 | 0.110 |
Why?
|
| Registries | 2 | 2019 | 1435 | 0.110 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2017 | 259 | 0.110 |
Why?
|
| Survival Analysis | 4 | 2017 | 1506 | 0.100 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 2176 | 0.100 |
Why?
|
| Embolization, Therapeutic | 1 | 2015 | 221 | 0.100 |
Why?
|
| Hospitalization | 1 | 2021 | 1790 | 0.100 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2017 | 557 | 0.100 |
Why?
|
| Immunotherapy | 1 | 2017 | 680 | 0.100 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2018 | 1140 | 0.090 |
Why?
|
| Referral and Consultation | 2 | 2013 | 543 | 0.090 |
Why?
|
| Quinazolines | 1 | 2012 | 175 | 0.090 |
Why?
|
| Quality of Life | 1 | 2021 | 1945 | 0.090 |
Why?
|
| Pancreatic Neoplasms | 1 | 2017 | 691 | 0.090 |
Why?
|
| Outpatients | 1 | 2013 | 257 | 0.090 |
Why?
|
| Antibodies, Monoclonal | 1 | 2017 | 1033 | 0.090 |
Why?
|
| Sensitivity and Specificity | 1 | 2016 | 2058 | 0.090 |
Why?
|
| Piperidines | 1 | 2012 | 209 | 0.090 |
Why?
|
| Patient Care Management | 1 | 2011 | 67 | 0.090 |
Why?
|
| Physicians, Primary Care | 1 | 2011 | 95 | 0.080 |
Why?
|
| Survival Rate | 3 | 2021 | 2062 | 0.080 |
Why?
|
| Perception | 1 | 2011 | 220 | 0.080 |
Why?
|
| Medical Oncology | 1 | 2011 | 217 | 0.080 |
Why?
|
| Gait | 2 | 2021 | 144 | 0.080 |
Why?
|
| Hospitals, Veterans | 1 | 2011 | 359 | 0.080 |
Why?
|
| Inpatients | 1 | 2013 | 500 | 0.080 |
Why?
|
| Prognosis | 1 | 2018 | 4648 | 0.080 |
Why?
|
| Lung Neoplasms | 2 | 2024 | 1659 | 0.070 |
Why?
|
| Qualitative Research | 1 | 2011 | 547 | 0.070 |
Why?
|
| Terminally Ill | 1 | 2008 | 28 | 0.070 |
Why?
|
| Attitude to Death | 1 | 2008 | 37 | 0.070 |
Why?
|
| Patient Care Team | 1 | 2011 | 546 | 0.070 |
Why?
|
| Attitude to Health | 1 | 2008 | 258 | 0.060 |
Why?
|
| Fear | 2 | 2021 | 199 | 0.060 |
Why?
|
| Gene Expression Profiling | 1 | 2011 | 1711 | 0.060 |
Why?
|
| Surveys and Questionnaires | 2 | 2011 | 3741 | 0.050 |
Why?
|
| Biomarkers, Tumor | 1 | 2011 | 1496 | 0.050 |
Why?
|
| Signal Transduction | 2 | 2012 | 4536 | 0.050 |
Why?
|
| Stress, Psychological | 1 | 2008 | 560 | 0.050 |
Why?
|
| Multivariate Analysis | 2 | 2017 | 1442 | 0.050 |
Why?
|
| Accidental Falls | 1 | 2021 | 104 | 0.040 |
Why?
|
| Obesity | 1 | 2011 | 2252 | 0.040 |
Why?
|
| Breast Neoplasms | 1 | 2011 | 2515 | 0.040 |
Why?
|
| Risk Assessment | 2 | 2018 | 3468 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2022 | 1397 | 0.040 |
Why?
|
| Exercise | 1 | 2024 | 816 | 0.040 |
Why?
|
| Age Factors | 2 | 2016 | 2827 | 0.040 |
Why?
|
| Attention | 1 | 2019 | 201 | 0.040 |
Why?
|
| Postural Balance | 1 | 2019 | 124 | 0.040 |
Why?
|
| Diplopia | 1 | 2017 | 39 | 0.030 |
Why?
|
| Memory Disorders | 1 | 2019 | 234 | 0.030 |
Why?
|
| Neoplasm, Residual | 1 | 2017 | 122 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2017 | 286 | 0.030 |
Why?
|
| Lymph Node Excision | 1 | 2017 | 166 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 2017 | 359 | 0.030 |
Why?
|
| Dyspnea | 1 | 2017 | 152 | 0.030 |
Why?
|
| Chemoembolization, Therapeutic | 1 | 2015 | 23 | 0.030 |
Why?
|
| Neuropsychological Tests | 1 | 2019 | 919 | 0.030 |
Why?
|
| Health Services | 1 | 2016 | 71 | 0.030 |
Why?
|
| alpha-Fetoproteins | 1 | 2016 | 132 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2017 | 620 | 0.030 |
Why?
|
| Liver Diseases, Alcoholic | 1 | 2016 | 57 | 0.030 |
Why?
|
| Biomarkers | 1 | 2024 | 3096 | 0.030 |
Why?
|
| Pandemics | 1 | 2022 | 1115 | 0.030 |
Why?
|
| Risk Factors | 2 | 2018 | 10331 | 0.030 |
Why?
|
| Independent Living | 1 | 2013 | 66 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2012 | 154 | 0.020 |
Why?
|
| Quality Improvement | 1 | 2017 | 646 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2019 | 3306 | 0.020 |
Why?
|
| Metabolic Syndrome | 1 | 2015 | 343 | 0.020 |
Why?
|
| Patient Admission | 1 | 2013 | 185 | 0.020 |
Why?
|
| ErbB Receptors | 1 | 2012 | 283 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2019 | 2917 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2011 | 435 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2012 | 412 | 0.020 |
Why?
|
| Reference Values | 1 | 2011 | 718 | 0.020 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2011 | 341 | 0.020 |
Why?
|
| Hepatitis C | 1 | 2013 | 367 | 0.020 |
Why?
|
| Time Factors | 1 | 2018 | 6345 | 0.020 |
Why?
|
| Existentialism | 1 | 2008 | 2 | 0.020 |
Why?
|
| Nursing Methodology Research | 1 | 2008 | 13 | 0.020 |
Why?
|
| Logistic Models | 1 | 2013 | 1815 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2011 | 1016 | 0.020 |
Why?
|
| Grief | 1 | 2008 | 19 | 0.020 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2012 | 541 | 0.020 |
Why?
|
| New York | 1 | 2008 | 68 | 0.020 |
Why?
|
| Prevalence | 1 | 2014 | 2467 | 0.020 |
Why?
|
| Receptors, Estrogen | 1 | 2011 | 794 | 0.020 |
Why?
|
| Spirituality | 1 | 2008 | 48 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2012 | 1122 | 0.020 |
Why?
|
| Disease Progression | 1 | 2013 | 2077 | 0.020 |
Why?
|
| Health Services Needs and Demand | 1 | 2008 | 175 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2015 | 5185 | 0.020 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2013 | 604 | 0.020 |
Why?
|
| Interpersonal Relations | 1 | 2008 | 230 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 2011 | 1699 | 0.020 |
Why?
|
| Activities of Daily Living | 1 | 2008 | 407 | 0.020 |
Why?
|
| Emergency Service, Hospital | 1 | 2013 | 1070 | 0.020 |
Why?
|
| Family | 1 | 2008 | 567 | 0.010 |
Why?
|
| Diabetes Mellitus | 1 | 2013 | 875 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2011 | 1897 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2011 | 6168 | 0.010 |
Why?
|
| Animals | 1 | 2012 | 34241 | 0.010 |
Why?
|